Antibiotic-induced Dysbiosis as a Putative Actionable Driver of Cancer Immunity in Renal Cell Carcinoma

David James PINATO

doi:10.1016/j.eururo.2020.05.006

Antibiotic-induced Dysbiosis as a Putative Actionable Driver of Cancer Immunity in Renal Cell Carcinoma

David James PINATO

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Lingua originale	Inglese
pagine (da-a)	207-208
Numero di pagine	2
Rivista	European Urology
Volume	78
Numero di pubblicazione	2
DOI	https://doi.org/10.1016/j.eururo.2020.05.006
Stato di pubblicazione	Pubblicato - 2020

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Accesso al documento

10.1016/j.eururo.2020.05.006

http://hdl.handle.net/11579/125765

Altri file e collegamenti

handle

Cita questo

@article{c3ce7f3887b64a6290e2139b4d0c56b5,

title = "Antibiotic-induced Dysbiosis as a Putative Actionable Driver of Cancer Immunity in Renal Cell Carcinoma",

author = "PINATO, \{David James\}",

note = "Funding Information: Acknowledgments: The author would like to acknowledge the Imperial College National Institute for Health Research (NIHR) Biomedical Research Centre and Imperial Cancer Research UK for infrastructural and grant funding support and the Wellcome Trust Strategic Fund ( PS3416 ). The views expressed are those of the author and not necessarily those of the NIHR or the Department of Health and Social Care.",

year = "2020",

doi = "10.1016/j.eururo.2020.05.006",

language = "English",

volume = "78",

pages = "207--208",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Antibiotic-induced Dysbiosis as a Putative Actionable Driver of Cancer Immunity in Renal Cell Carcinoma

AU - PINATO, David James

N1 - Funding Information: Acknowledgments: The author would like to acknowledge the Imperial College National Institute for Health Research (NIHR) Biomedical Research Centre and Imperial Cancer Research UK for infrastructural and grant funding support and the Wellcome Trust Strategic Fund ( PS3416 ). The views expressed are those of the author and not necessarily those of the NIHR or the Department of Health and Social Care.

PY - 2020

Y1 - 2020

UR - https://iris.uniupo.it/handle/11579/125765

U2 - 10.1016/j.eururo.2020.05.006

DO - 10.1016/j.eururo.2020.05.006

M3 - Article

SN - 0302-2838

VL - 78

SP - 207

EP - 208

JO - European Urology

JF - European Urology

IS - 2

ER -